OverviewChartNewsTraderScreen

Soc. Generale Knock-Out BMRN/  DE000SU4VCN0  /

Frankfurt Zert./SG
5/21/2024  2:33:00 PM Chg.-0.100 Bid3:03:11 PM Ask3:03:11 PM Underlying Strike price Expiration date Option type
3.620EUR -2.69% 3.640
Bid Size: 4,000		 3.750
Ask Size: 4,000		 BioMarin Pharmaceuti... 116.9266 USD 12/31/2078 Put
GlobeNewswire 5/8 Terns Pharmaceuticals Announces Leadership Changes
GlobeNewswire 11/2/2023 California Life Sciences announces 20th annual Pantheon Award winners
GlobeNewswire 10/2/2023 California’s top scientific innovators selected as finalists for the 20th annual California Life Sci...
GlobeNewswire 3/1/2022 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corpor...
GlobeNewswire 2/14/2022 Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
Newsfile Corp 2/4/2022 SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
GlobeNewswire 1/24/2022 SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
GlobeNewswire 12/23/2021 Lifshitz Law Firm, P.C. Announces Investigations of Amarin Corporation plc (NASDAQGM: AMRN), BioMari...
GlobeNewswire 12/21/2021 BMRN FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioMarin Pharmaceutical Inc....
GlobeNewswire 12/20/2021 BMRN & RECAF – Upcoming Lead Deadlines: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 12/20/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 12/17/2021 ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure C...
GlobeNewswire 12/7/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 12/7/2021 ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Befor...
GlobeNewswire 12/1/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 11/30/2021 AMRN, BMRN & RECAF – Upcoming Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 11/28/2021 ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losse...
GlobeNewswire 11/19/2021 AMRN, BMRN & RECAF – Class Actions Deadlines: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 11/15/2021 Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
GlobeNewswire 11/13/2021 ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Lo...
GlobeNewswire 11/12/2021 AMRN, BMRN & RECAF – Class Action Alerts: Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire 11/10/2021 INVESTOR REMINDER: BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) SHAREHOLDER CLASS ACTION DEADLINE- Be...
GlobeNewswire 11/9/2021 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMar...
GlobeNewswire 11/9/2021 BIOMARIN DEADLINE ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Enco...
GlobeNewswire 11/3/2021 BMRN INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutica...